Covalab invests more than €1 million in bioproduction operations for antibodies for Covid-19 diagnostics
Company’s BioDiaThera project received almost €500,000 in subsidies as part of French ‘Capacity Building’ scheme
25-May-2022 -
Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and antibodies for diagnostics and therapeutics, announces that its BioDiaThera project has been awarded €491,152 ($520k) in funding as part of the French ‘Capacity Building’ scheme; part ...
antibodies
biopharmaceutical manufacturing
Coronavirus testing
+5